Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers

被引：0
|
作者：
Murphy, Eric A.
Bartberger, Michael D.
Ibanez, Maureen
Smith, Troy T.
Alvarez, Nicole
Timple, Noel
Zhu, Xuefeng
Fan, Kevin
Yu, Kevin
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB173
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB173
引用
收藏
页数：2
相关论文
共 8 条
  • [1] Absence of E17K mutation in the pleckstrin homology domain of AKT1 in gastrointestinal and liver cancers in the Korean population
    Cao, Zhang
    Song, Jae Hwi
    Kim, Chang Jae
    Cho, Yong Gu
    Kim, Su Young
    Nam, Suk Woo
    Lee, Jung Young
    Park, Won Sang
    APMIS, 2008, 116 (06) : 530 - 533
  • [2] Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer
    Bose, Sminu
    Kalinsky, Kevin
    CLINICAL BREAST CANCER, 2021, 21 (03) : E150 - E153
  • [3] Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
    Mancini, Maria L.
    Lien, Evan C.
    Toker, Alex
    ONCOTARGET, 2016, 7 (14) : 17301 - 17313
  • [4] Discovery of ARQ 092: A potent, selective allosteric inhibitor of AKT1, 2, 3 and AKT1-E17K in clinical development for cancer and rare diseases
    Lapierre, Jean-Marc
    Eathiraj, Sudharshan
    Yu, Yi
    Savage, Ronald
    Abbadessa, Giovanni
    Schwartz, Brian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [5] A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1
    Deyle K.M.
    Farrow B.
    Qiao Hee Y.
    Work J.
    Wong M.
    Lai B.
    Umeda A.
    Millward S.W.
    Nag A.
    Das S.
    Heath J.R.
    Nature Chemistry, 2015, 7 (5) : 455 - 462
  • [6] A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1
    Deyle, Kaycie M.
    Farrow, Blake
    Hee, Ying Qiao
    Work, Jeremy
    Wong, Michelle
    Lai, Bert
    Umeda, Aiko
    Millward, Steven W.
    Nag, Arundhati
    Das, Samir
    Heath, James R.
    Nature Chemistry, 2015, 7 (05) : 455 - 462
  • [7] ATV-1601 is a Potent and Selective Allosteric Inhibitor of AKT1-E17K and Shows Profound and Durable Regressions in AKT1-E17K-Driven Patient Derived Xenograft Models
    Schinzel, A. C.
    Coffin, A.
    Pham, T.
    Brigham, B.
    Iantosca, G.
    Govindaraj, R.
    LaPointe, J.
    Prescott-Roy, J.
    Church, D.
    Murray, G.
    Roddy, T.
    Padyana, A. K.
    Dorsch, M.
    Sengupta, S.
    Blanco, M. J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S57 - S57
  • [8] Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363).
    Smyth, Lillian Mary
    Reichel, Jonathan B.
    Tang, Jiabin
    Patel, Juber Ahamad A.
    Meng, Fanli
    Selcuklu, S. Duygu
    You, Daoqi
    Samoila, Aliaksandra
    Schiavon, Gaia
    Li, Bob T.
    Razavi, Pedram
    Piscuoglio, Salvatore
    Reis-Filho, Jorge S.
    Nudis, Clifford A.
    Baselga, Jose
    Solit, David B.
    Taylor, Barry S.
    Hyman, David Michael
    Berger, Michael F.
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1